|
rs776746
|
CYP3A5;ZSCAN25
|
Epilepsy
|
|
0.010 |
GeneticVariation |
BEFREE |
rs776746 and rs15524 in the CYP3A5 gene tend to affect CBZ metabolism, and rs2032582, rs10234411 in the ABCB1 gene may contribute to inter-individual variation in CBZ and in CBZ-E transport among patients with epilepsy using CBZ in combination with PHT or PB.
|
26421491 |
2015 |
|
rs776746
|
CYP3A5;ZSCAN25
|
Connective Tissue Diseases
|
|
0.010 |
GeneticVariation |
BEFREE |
A total of 72 patients with CTD were recruited in the current study and genotyped for rs776746 in CYP3A5, which showed strong association with TAC concentration in patients with solid organ transplantation.
|
24352002 |
2014 |
|
rs776746
|
CYP3A5;ZSCAN25
|
Leukopenia
|
|
0.010 |
GeneticVariation |
BEFREE |
Although univariate analysis in all patients did not reveal any association at first, further analysis indicated that rs776746 is significantly associated with severe neutropenia in subgroup of breast cancer patients with normal baseline ANC (≥2.0 × 10(9)/L).
|
23143606 |
2013 |
|
rs776746
|
CYP3A5;ZSCAN25
|
Neutropenia
|
|
0.010 |
GeneticVariation |
BEFREE |
Although univariate analysis in all patients did not reveal any association at first, further analysis indicated that rs776746 is significantly associated with severe neutropenia in subgroup of breast cancer patients with normal baseline ANC (≥2.0 × 10(9)/L).
|
23143606 |
2013 |
|
rs776746
|
CYP3A5;ZSCAN25
|
Malignant neoplasm of breast
|
|
0.010 |
GeneticVariation |
BEFREE |
Although univariate analysis in all patients did not reveal any association at first, further analysis indicated that rs776746 is significantly associated with severe neutropenia in subgroup of breast cancer patients with normal baseline ANC (≥2.0 × 10(9)/L).
|
23143606 |
2013 |
|
rs776746
|
CYP3A5;ZSCAN25
|
Breast Carcinoma
|
|
0.010 |
GeneticVariation |
BEFREE |
Although univariate analysis in all patients did not reveal any association at first, further analysis indicated that rs776746 is significantly associated with severe neutropenia in subgroup of breast cancer patients with normal baseline ANC (≥2.0 × 10(9)/L).
|
23143606 |
2013 |
|
rs776746
|
CYP3A5;ZSCAN25
|
Myeloid Leukemia, Chronic
|
|
0.010 |
GeneticVariation |
BEFREE |
Contrasting results have been reported on the role of rs628031 and rs683369 polymorphisms of SLC22A1 and rs776746 of CYP3A5 on imatinib treatment response in patients with chronic myeloid leukemia (CML).
|
29427770 |
2018 |
|
rs776746
|
CYP3A5;ZSCAN25
|
Tuberculosis
|
|
0.020 |
GeneticVariation |
BEFREE |
CYP2C19 (636 G>A, rs4986893) A allele and AG genotype were associated with decreased susceptibility to TB (P = 0.006, OR= 0.33, 95% CI: 0.15-0.76; and P = 0.005, OR =0.31, 95% CI: 0.14-0.72 respectively), as were the CYP3A5 (6986A>G, rs776746) G allele and particularly homozygous GG (recessive mode) genotype (P = 0.004, OR=0.61, 95% CI: 0.43-0.85; and P=0.002, OR=0.47, 95% CI: 0.29-0.76).
|
22771593 |
2012 |
|
rs1474798132
|
CYP3A5;ZSCAN25
|
Tuberculosis
|
|
0.010 |
GeneticVariation |
BEFREE |
CYP2C19 (636 G>A, rs4986893) A allele and AG genotype were associated with decreased susceptibility to TB (P = 0.006, OR= 0.33, 95% CI: 0.15-0.76; and P = 0.005, OR =0.31, 95% CI: 0.14-0.72 respectively), as were the CYP3A5 (6986A>G, rs776746) G allele and particularly homozygous GG (recessive mode) genotype (P = 0.004, OR=0.61, 95% CI: 0.43-0.85; and P=0.002, OR=0.47, 95% CI: 0.29-0.76).
|
22771593 |
2012 |
|
rs777175289
|
CYP3A5;ZSCAN25
|
Non-Small Cell Lung Carcinoma
|
|
0.010 |
GeneticVariation |
BEFREE |
CYP2C19*2(G681A), CYP2C19*3(G636A), CYP2D6*4(C188T), CYP2D6*2(C2938T, G4268C), CYP3AP1*3- G44A and CYP3A5*3(A22893G) are the most common polymorphisms detected among Chinese that may influence the efficacy of vinorelbine-based therapies to treat non-small-cell lung cancer (NSCLC).
|
17450472 |
2007 |
|
rs1474798132
|
CYP3A5;ZSCAN25
|
Non-Small Cell Lung Carcinoma
|
|
0.010 |
GeneticVariation |
BEFREE |
CYP2C19*2(G681A), CYP2C19*3(G636A), CYP2D6*4(C188T), CYP2D6*2(C2938T, G4268C), CYP3AP1*3- G44A and CYP3A5*3(A22893G) are the most common polymorphisms detected among Chinese that may influence the efficacy of vinorelbine-based therapies to treat non-small-cell lung cancer (NSCLC).
|
17450472 |
2007 |
|
rs776746
|
CYP3A5;ZSCAN25
|
Secondary malignant neoplasm of colon and/or rectum
|
|
0.010 |
GeneticVariation |
BEFREE |
CYP3A5 rs776746 A>G polymorphisms have a prognostic contribution toward FOLFIRI regimen in mCRC.
|
25934339 |
2015 |
|
rs4646450
|
CYP3A5;ZSCAN25
|
Acute lymphocytic leukemia
|
|
0.010 |
GeneticVariation |
BEFREE |
CYP3A5 rs4646450 TT was 17% among ALL cases with FS lower than 28, and 3% in ALL patients without pathological FS (p = 5.60E-03; OR = 6.94 (1.76-27.39)).
|
29970035 |
2018 |
|
rs4646450
|
CYP3A5;ZSCAN25
|
Childhood Acute Lymphoblastic Leukemia
|
|
0.010 |
GeneticVariation |
BEFREE |
CYP3A5 rs4646450 TT was 17% among ALL cases with FS lower than 28, and 3% in ALL patients without pathological FS (p = 5.60E-03; OR = 6.94 (1.76-27.39)).
|
29970035 |
2018 |
|
rs4646450
|
CYP3A5;ZSCAN25
|
Adult Acute Lymphocytic Leukemia
|
|
0.010 |
GeneticVariation |
BEFREE |
CYP3A5 rs4646450 TT was 17% among ALL cases with FS lower than 28, and 3% in ALL patients without pathological FS (p = 5.60E-03; OR = 6.94 (1.76-27.39)).
|
29970035 |
2018 |
|
rs4646450
|
CYP3A5;ZSCAN25
|
Hormone measurement
|
|
0.700 |
GeneticVariation |
GWASDB |
Eight common genetic variants associated with serum DHEAS levels suggest a key role in ageing mechanisms.
|
21533175 |
2011 |
|
rs776746
|
CYP3A5;ZSCAN25
|
Cerebrovascular accident
|
|
0.020 |
GeneticVariation |
BEFREE |
Eight variants in five candidate genes were examined for the risk of stroke, including the SG13S32 (rs9551963), SG13S42 (rs4769060), SG13S89 (rs4769874), and SG13S114 (rs10507391) variants of the 5-lipoxygenase activating protein (ALOX5AP) gene, the G860A (rs751141) variant of the soluble epoxide hydrolase (EPHX2) gene, the A1075C (rs1057910) variant of the CYP2C9*2 gene, the C430T (rs1799853) variant of the CYP2C9*3 gene, and the A6986G (rs776746) variant of the CYP3A5 gene.
|
24368493 |
2014 |
|
rs776746
|
CYP3A5;ZSCAN25
|
Carcinogenesis
|
|
0.010 |
GeneticVariation |
BEFREE |
Emerging evidences suggest that CYP3A5*3 (rs776746 A>G) polymorphism may play a role in the etiology of carcinogenesis and affect an individual's susceptibility to cancer in humans, but individually published studies showed inconclusive results.
|
23584898 |
2013 |
|
rs776746
|
CYP3A5;ZSCAN25
|
Malignant Neoplasms
|
|
0.010 |
GeneticVariation |
BEFREE |
Emerging evidences suggest that CYP3A5*3 (rs776746 A>G) polymorphism may play a role in the etiology of carcinogenesis and affect an individual's susceptibility to cancer in humans, but individually published studies showed inconclusive results.
|
23584898 |
2013 |
|
rs776746
|
CYP3A5;ZSCAN25
|
Primary malignant neoplasm
|
|
0.010 |
GeneticVariation |
BEFREE |
Emerging evidences suggest that CYP3A5*3 (rs776746 A>G) polymorphism may play a role in the etiology of carcinogenesis and affect an individual's susceptibility to cancer in humans, but individually published studies showed inconclusive results.
|
23584898 |
2013 |
|
rs12333599
|
CYP3A5;ZSCAN25
|
Platelet Count measurement
|
|
0.700 |
GeneticVariation |
GWASCAT |
Genetic analysis of quantitative traits in the Japanese population links cell types to complex human diseases.
|
29403010 |
2018 |
|
rs41303343
|
CYP3A5;ZSCAN25
|
ASSAY FOR TACROLIMUS
|
|
0.700 |
GeneticVariation |
GWASCAT |
Genetic Variants Associated With Immunosuppressant Pharmacokinetics and Adverse Effects in the DeKAF Genomics Genome-wide Association Studies.
|
30801552 |
2019 |
|
rs776746
|
CYP3A5;ZSCAN25
|
ASSAY FOR TACROLIMUS
|
|
0.700 |
GeneticVariation |
GWASCAT |
Genetic Variants Associated With Immunosuppressant Pharmacokinetics and Adverse Effects in the DeKAF Genomics Genome-wide Association Studies.
|
30801552 |
2019 |
|
rs776746
|
CYP3A5;ZSCAN25
|
Chronic Obstructive Airway Disease
|
|
0.010 |
GeneticVariation |
BEFREE |
In this study, we compared genetic variants influencing the effect of smoking on COPD, that is, the effect of the well-known splicing defect polymorphism, CYP3A5*3 (rs776746), identified before genome-wide association studies, with the genome-wide association studies identified CHRNA3 (rs1051730) polymorphism on the risk of decreased lung function and COPD.
|
24535486 |
2014 |
|
rs776746
|
CYP3A5;ZSCAN25
|
Hypertensive disease
|
|
0.040 |
GeneticVariation |
BEFREE |
Our finding suggested that wild-type CYP3A4 rs2242480 (TT) carriers should be more cautious to take tacrolimus when they are coadministrated with calcium channel blockers, and CYP3A5 rs776746 (AA) carriers may need higher tacrolimus dosage when they are in combination with hypertension.
|
30861159 |
2019 |